Plain-English translation of NCT06062745 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a pilot study testing whether a medication called can help doctors see certain types of advanced prostate cancer that are hard to detect with standard imaging. The medication is already approved by the FDA for early prostate cancer, but this study is the first time researchers are examining whether it works for more aggressive forms of the disease, including cancers that have become resistant to hormone therapy or have changed into neuroendocrine cancer. The goal is to determine if this medication can spot these harder-to-find tumors.
Some advanced prostate cancers don't show up well on standard imaging tests, which makes it difficult for doctors to find all the cancer in the body and plan the best treatment. This study exists to see if the new medication can help doctors visualize these 'hidden' tumors by targeting the way cancer cells use amino acids for energy—an approach that may work better than current methods.
You likely qualify if…
You likely don't qualify if…
You will receive a standard imaging scan (called 68Ga-PSMA PET/CT) as part of your normal care, and then within 6 weeks you will have an additional research imaging scan using . You will also provide two blood samples—one at the time of your research scan and another before you start any new cancer treatment as decided with your doctor. The entire study involves these two imaging tests and two blood draws; there is no daily medication to take at home.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States